Abstract: In some example implementations, there is provided an apparatus. The apparatus may include a plurality of prism portions configured to shift light passing through the apparatus including the plurality of prisms portions, and a plurality of portions configured to pass light unshifted through the apparatus, wherein the apparatus combines the shifted light and the unshifted light passing through the apparatus. Related apparatus are also disclosed.
Type:
Grant
Filed:
February 20, 2014
Date of Patent:
July 24, 2018
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: In some example implementations, there is provided a method for predicting retinal degeneration in multiple eye diseases. The method may include receiving three-dimensional data representative of a plurality of layers of a retina of a subject under test; determining, from the received data, oxygen concentration at one or more of the plurality of layers; detecting, based on the determined oxygen concentration, a region of at least one a high oxygen concentration in the retina or a low oxygen concentration in the retina; and comparing the detected region to reference data to determine whether the retina including the detected region suffers from or will suffer from at least one of a retinal disease or a degeneration of the retina. Related apparatus are also disclosed.
Type:
Grant
Filed:
April 23, 2014
Date of Patent:
June 5, 2018
Assignee:
The Schepens Eye Research Institute, Inc.
Inventors:
Kevin McHugh, Magali Saint-Geniez, Leo Kim
Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
Type:
Application
Filed:
October 30, 2017
Publication date:
March 8, 2018
Applicants:
VA Boston Healthcare System, Schepens Eye Research Institute, Children's Medical Center Corporation
Inventors:
Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
Abstract: In some example implementations, there is provided a method. The method may include determining a probabilistic model representing threshold sensitivities across the visual field, the probabilistic model determined based on the data, the connection strengths, and the noise values. Related systems, methods, and articles of manufacture are also disclosed. In some implementations, the probabilistic model may include a continuous probability distribution.
Type:
Grant
Filed:
August 22, 2014
Date of Patent:
February 6, 2018
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
Type:
Grant
Filed:
March 7, 2016
Date of Patent:
January 23, 2018
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Type:
Application
Filed:
June 2, 2017
Publication date:
November 23, 2017
Applicant:
The Schepens Eye Research Institute
Inventors:
Michael J. Young, Budd A. Tucker, Petr Y. Baranov
Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
Type:
Grant
Filed:
February 19, 2014
Date of Patent:
October 31, 2017
Assignees:
VA Boston Healthcare System, Schepens Eye Research Institute, Children's Medical Center Corporation
Inventors:
Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
August 15, 2017
Assignees:
Thc Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
Type:
Grant
Filed:
May 24, 2010
Date of Patent:
August 15, 2017
Assignees:
Lubris, LLC, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Edward R. Truitt, David Sullivan
Abstract: In some implementations, there is provided a method. The method may include receiving data characterizing a plurality of digital video frames; detecting a plurality of features in each of the plurality of digital video frames; determining, from the detected features, a local scale change and a translational motion of one or more groups of features between at least a pair of the plurality of digital video frames; and calculating a likelihood of collision. Related apparatus, systems, techniques, and articles are also described.
Type:
Grant
Filed:
September 20, 2013
Date of Patent:
August 15, 2017
Assignee:
The Schepens Eye Research Institute, Inc.
Inventors:
Gang Luo, Eliezer Peli, Shrinivas Pundlik
Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
Type:
Grant
Filed:
October 12, 2016
Date of Patent:
August 1, 2017
Assignees:
Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute
Abstract: Data is received characterizing a result of a first visual sensitivity test assessing capacity to detect spatial form across one or more different target sizes, and different contrasts. Using the received data, one or more first parameters defining a first estimated visual sensitivity for a first range of contrasts and a second range of spatial frequencies is determined. One or more second parameters defining a second estimated visual sensitivity for a third range of contrasts and a fourth range of spatial frequencies is determined using the one or more first parameters and a statistical inference by at least presenting a first visual stimulus, receiving a response, and determining a second visual stimulus based at least on the response and at least a rule. The one or more second parameters is provided. Related apparatus, systems, techniques and articles are also described.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
July 11, 2017
Assignees:
The Schepens Eye Research Institute, Inc., The Ohio State University
Inventors:
Peter Bex, Michael Dorr, Luis Lesmes, Zhong-Lin Lu
Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
Type:
Grant
Filed:
April 11, 2016
Date of Patent:
July 4, 2017
Assignees:
Massachusetts Eye & Ear Infirmary, Schepens Eye Research Institute
Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Type:
Grant
Filed:
October 17, 2013
Date of Patent:
June 13, 2017
Assignee:
The Schepens Eye Research Institute
Inventors:
Michael J. Young, Budd A. Tucker, Petr Y. Baranov
Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
March 7, 2017
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
Type:
Grant
Filed:
August 20, 2015
Date of Patent:
August 23, 2016
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
July 19, 2016
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan